Litigation Details for UNITED THERAPEUTICS CORPORATION v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

UNITED THERAPEUTICS CORPORATION v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

Docket		Date Filed	2014-09-02
Court	District Court, D. New Jersey	Date Terminated	2016-01-15
Cause	35:271 Patent Infringement	Assigned To	Peter G. Sheridan
Jury Demand	Plaintiff	Referred To	Magistrate Judge Lois H. Goodm
Patents	6,765,117; 7,999,007; 8,497,393; 8,653,137; 8,658,694
Link to Docket	External link to docket

Details for UNITED THERAPEUTICS CORPORATION v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-09-02	1		seq., involving United States Patent Nos. 6,765,117 (“the ’117 patent”) (attached as Exhibit A hereto…of the ’117 patent, the ’393 patent, the ’007 patent, the ’137 patent, and the ’694 patent, which have… the ’117 patent the ’393 patent, the ’007 patent, the ’137 patent, and/or the ’694 patent, inclusive… the ’117 patent the ’393 patent, the ’007 patent, the ’137 patent, and/or the ’694 patent, including… the ’117 patent the ’393 patent, the ’007 patent, the ’137 patent, and/or the ’694 patent, inclusive	External link to document
2015-12-02	85		of the term “a base B” in U.S. Patent No. 8,497,393 (“the ‘393 patent”). After reviewing the parties’… It is a bedrock principle of patent law that the claims of a patent define the invention…issue in the ‘393 patent is “a base B”. Initially, the term “a” is defined in the patent as “one or more… By way of background, the‘393 patent is a product-by-process patent for a more efficient way to develop…inventors in the related ‘305 patent. In the prosecutorial history of the ‘305 Patent, the inventors described	External link to document